GlassScriptPhysician profile
Debbie A Cihak
NPI 1417908906
$1,070.40
in general payments reported to CMS, 2019-2025
21 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $370 · 2022: $117 · 2023: $197 · 2024: $190 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $202.15 | 2021-2024 | Qulipta, Ubrelvy |
| Ucb, INC. | $109.26 | 2021-2024 | Fintepla, Nayzilam |
| Amgen INC. | $103.24 | 2022-2025 | Otezla, Repatha, Prolia |
| Astellas Pharma US INC | $102.95 | 2023-2025 | Veozah |
| Sk Life Science, INC. | $74.66 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $62.45 | 2021-2025 | |
| Beta Bionics, INC. | $58.65 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amneal Pharmaceuticals LLC | $47.29 | 2022-2023 | Rytary |
| Teva Pharmaceuticals USA, INC. | $42.05 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $39.57 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $36.96 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.16 | 2022 | |
| Argenx US, INC. | $24.28 | 2022 | |
| Pfizer INC. | $21.16 | 2025 | |
| Sumitomo Pharma America, INC. | $20.26 | 2023 | Gemtesa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $18.66 | 2025 | Rexulti |
| Exact Sciences Corporation | $17.24 | 2025 | Cologuard Collection Kit |
| Kyowa Kirin, INC. | $16.46 | 2024 | Nourianz |
| Glaxosmithkline, LLC. | $15.77 | 2021 | |
| Merz Pharmaceuticals, LLC | $15.42 | 2025 | Xeomin |
| Acadia Pharmaceuticals INC | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Cihak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.